Urokinase-type plasminogen activator (u-PA) contributes to prostate cancer progression. In vitro, u-PA is expressed by androgen-insensitive, but not androgen-sensitive, prostate cancer cell lines. We hypothesized that binding the dihydrotestosterone/androgen receptor complex to a hormone response element (HRE) in the u-PA promoter region represses u-PA transcription in androgen-sensitive prostate cancer. In androgen-insensitive prostate cancer, however, lack of androgen receptors permit increased u-PA transcription, which is mediated through the AP-1 transcription factor binding site.
Method
We identi®ed an HRE with the sequence TGTTCT in the u-PA promoter region. Two PC3 cell lines stably transfected with the androgen receptor (PC3(AR) 2 and PC3(AR) 13 ) and one mock-transfected cell line (PC3(M)) were acquired from Dr Theodore Brown at the University of Toronto. Cells grown in phenol-red-free/charcoalstripped medium were then changed to either serumfree medium, 0.1 nM mibolerone (a synthetic androgen), 15 mM¯utamide or mibolerone plus¯utamide.
Results
In the presence of mibolerone, conditioned media assayed by Western and Northern blotting showed decreased u-PA expression by both PC3(AR) 2 and PC3(AR) 13 , but not the PC3(M) cells. Flutamide abrogated mibolerone's effect. We performed transient transfections in androgen-insensitive PC3 cells using u-PA promoter-regulated CAT reporter constructs. The u-PA promoter was either wild-type, or associated with the deletion or mutation of the 5 0 AP-1 transcriptional factor binding site. Compared with full-length u-PA promoter CAT constructs, either deletion or mutation of the 5 0 AP-1 site resulted in reduced CT expression.
Conclusion
These data suggest that, in androgen-sensitive prostate cancer, an activated HRE dominantly represses u-PA expression, whereas in androgen-insensitive prostate cancer AP-1 binding-site activation mediates its upregulation.
